HighTower Advisors LLC lowered its stake in shares of The Cooper Companies, Inc. (NYSE:COO – Get Rating) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,462 shares of the medical device company’s stock after selling 67 shares during the period. HighTower Advisors LLC’s holdings in Cooper Companies were worth $1,480,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Greenwood Capital Associates LLC purchased a new stake in Cooper Companies during the fourth quarter worth about $25,000. Belpointe Asset Management LLC purchased a new stake in Cooper Companies during the fourth quarter worth about $30,000. CI Investments Inc. lifted its holdings in shares of Cooper Companies by 60.7% in the third quarter. CI Investments Inc. now owns 135 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 51 shares in the last quarter. Standard Family Office LLC purchased a new stake in shares of Cooper Companies in the third quarter valued at about $37,000. Finally, General Partner Inc. purchased a new stake in shares of Cooper Companies in the fourth quarter valued at about $37,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on COO. StockNews.com began coverage on shares of Cooper Companies in a report on Thursday, May 18th. They issued a “hold” rating on the stock. Stifel Nicolaus upped their price objective on shares of Cooper Companies from $380.00 to $420.00 in a research note on Tuesday, May 16th. Robert W. Baird upped their price objective on shares of Cooper Companies from $371.00 to $385.00 in a research note on Friday, March 3rd. Citigroup upped their price objective on shares of Cooper Companies from $372.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Finally, TheStreet raised shares of Cooper Companies from a “c+” rating to a “b-” rating in a research note on Friday, April 14th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average target price of $398.80.
Insider Transactions at Cooper Companies
Cooper Companies Stock Performance
Shares of COO stock opened at $371.44 on Friday. The Cooper Companies, Inc. has a one year low of $244.21 and a one year high of $395.20. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.00 and a current ratio of 1.72. The company has a 50 day moving average price of $374.74 and a 200 day moving average price of $345.80. The firm has a market capitalization of $18.37 billion, a price-to-earnings ratio of 49.20, a price-to-earnings-growth ratio of 2.72 and a beta of 0.91.
Cooper Companies (NYSE:COO – Get Rating) last released its quarterly earnings data on Thursday, March 2nd. The medical device company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.66 by $0.24. Cooper Companies had a net margin of 11.10% and a return on equity of 8.39%. The company had revenue of $858.50 million during the quarter, compared to analyst estimates of $834.90 million. During the same quarter in the prior year, the business earned $3.24 earnings per share. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 12.73 EPS for the current year.
Cooper Companies Profile
The Cooper Cos, Inc operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.
- Get a free copy of the StockNews.com research report on Cooper Companies (COO)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.